Beclometasone hydrofluoroalkane inhalation - 3M

Drug Profile

Beclometasone hydrofluoroalkane inhalation - 3M

Alternative Names: Beclometasone dipropionate hydrofluoroalkane inhalation - 3M; Beclometasone HFA inhalation - 3M; Beclometasone pressurised metered-dose inhalation - 3M; Beclomethasone breath-activated inhalation - 3M; Beclomethasone dipropionate hydrofluoroalkane inhalation - 3M; Beclomethasone HFA inhalation - 3M; Beclomethasone hydrofluoroalkane inhalation - 3M; HFA-134a BDP; Hydrofluoroalkane-134a beclomethasone dipropionate; Junik; Nexxair®; Qvar; Qvar Autohaler; Qvar BAI; Qvar Easi-Breathe; Qvarspray; Ventolair

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator 3M Pharmaceuticals
  • Developer 3M Pharmaceuticals; Teva Branded Pharmaceutical Products R&D
  • Class Antiallergics; Antiasthmatics; Chlorinated steroids; Corticosteroids; Pregnadienetriols; Small molecules; Vascular disorder therapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 03 Mar 2017 Adverse events and efficacy data from a phase III trial in Asthma presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2017)
  • 10 Nov 2016 Efficacy and safety data from a phase III trial in Asthma presented at the 2016 Annual Scientific Meeting of the American College of Asthma, Allergy & Immunology (ACAAI - 2016)
  • 10 Nov 2016 Pharmacokinetics and adverse event data from a phase I trial in Healthy volunteers presented at the 2016 Annual Scientific Meeting of the American College of Asthma, Allergy & Immunology (ACAAI - 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top